Lords Mark Industries Ltd (501261)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Lords Mark's revenue was ₹308 Cr, and net profit ₹33.2 Cr; the operating margin was 16.0%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹308 | — | -37.3% |
| Operating profit | ₹49.2 | — | -18.1% |
| Net profit | ₹33.2 | — | -17.0% |
| EPS (₹) | 0.78 | from loss | -16.1% |
| Operating margin | 16.0% | — | — |
📢 Recent Corporate Announcements
Lord's Mark Industries has completed the 100% acquisition of Radio Electric Private Limited (known for the 'Radiotone' brand) for a cash consideration of ₹4.50 crore. Founded in 1939, Radio Electric is a debt-free, profitable manufacturer of variable autotransformers and power-control solutions with repeat exports across 7 international markets. The acquisition price is modest relative to Lords Mark's TTM revenue of ₹993 crore (<0.5%), funded entirely via cash. The target's existing manufacturing facility operates at approximately 50% single-shift capacity, offering headroom to support Lords Mark's Battery Energy Storage Systems (BESS) and medical devices divisions.
- 100% equity control acquired in Radio Electric Private Limited for ₹4.50 Cr in cash
- Target is debt-free with an 87-year engineering heritage (founded in 1939)
- Existing manufacturing facility operates at ~50% single-shift capacity, enabling immediate scale-up
- Secures repeat export channels across 7 international markets including Europe, USA, and Canada
- Target client base spans 40-50 domestic blue-chip accounts
Lord's Mark Industries has acquired Radio Electric Private Limited, owner of the 'Radiotone' brand founded in 1939, under its Lighting & Energy Division. The target is a debt-free, profitable manufacturer of specialised variable autotransformers (Variacs) and toroidal transformers, currently operating at roughly 50% capacity on a single shift. Radio Electric brings an active base of 40-50 corporate clients, including L&T and Siemens, along with export reach into seven countries. While financial terms such as deal consideration were not disclosed in the filing, management intends to scale the unit's capacity and leverage it for BESS and medical device applications.
- Acquires 87-year-old Radio Electric Private Limited, established in 1939 with the Radiotone brand operating since 1980
- Target operates as a profitable, debt-free business running at ~50% machine capacity on a single shift
- Brings an established customer base of 40-50 industrial clients (including Siemens, Hitachi Hi-Rel, L&T, and Bharat Bijlee)
- Exports to 7 international markets, including Europe, the US, Canada, South Africa, Dubai, and the Philippines
- Former leadership consultant Umesh Marathe retained for 1 year to ensure smooth technical and process transfer
Lord's Mark Industries Limited has received registration from the UK's MHRA for its In Vitro Diagnostic (IVD) portfolio, dated September 24, 2026. The approval covers haematological cell analysers, clinical chemistry analysers, diluents, and cleaning agents. Commercial sales in the UK are planned to commence in December 2026, two months ahead of schedule, followed by pathology lab operations starting in January 2027. This follows the company's previous MHRA approval for its AI-powered Renalyx haemodialysis system as it expands in the UK and allied markets.
- MHRA registration received on September 24, 2026, recording the company as a registered manufacturer
- Covers IVD portfolio including haematological cell analysers, clinical chemistry analysers, buffered diluents, and cleaning agents
- UK commercial sales planned to begin in December 2026, approximately 2 months ahead of schedule
- Pathology laboratory operations scheduled to commence in January 2027
Promoter Mr. Sachidanand Hariram Upadhyay sold 89,98,598 equity shares of Lords Mark Industries via open market on September 29, 2026, generating net proceeds of Rs 76.18 crore. The promoter has confirmed and proposed to re-invest the majority of these proceeds into the company for the strategic expansion of its medical device unit. The re-investment mechanism will be finalized through viable and acceptable regulatory means, potentially injecting fresh capital into operations.
- Promoter sold 89,98,598 equity shares (face value Rs 10 each) on September 29, 2026
- Net proceeds realized from the share sale totaled Rs 76,18,19,624
- Majority of the Rs 76.18 crore proceeds proposed to be re-invested into the company's medical device unit expansion
Promoter Sachidanand Hariram Upadhyay sold 89,98,598 equity shares representing a 2.11% stake in Lords Mark Industries Limited through open market transactions on September 29, 2026. Following the disposal, his individual holding decreased from 32,04,39,246 shares (75.11%) to 31,14,40,648 shares (73.00%). The total equity base remained unchanged at 42,66,22,217 shares of Rs 10 each.
- Promoter Sachidanand Hariram Upadhyay sold 89,98,598 equity shares, or 2.11% of total share capital
- Holding decreased from 75.11% (32,04,39,246 shares) to 73.00% (31,14,40,648 shares)
- Transaction was executed through the open market on September 29, 2026
- Total paid-up equity capital remains at Rs 426,62,22,170 consisting of 42,66,22,217 equity shares of Rs 10 each
Promoter Sachidanand Hariram Upadhyay sold 89,98,598 equity shares representing a 2.11% stake in Lords Mark Industries Limited through open market transactions on September 29, 2026. Following the disposal, his individual holding decreased from 32,04,39,246 shares (75.11%) to 31,14,40,648 shares (73.00%). The total equity base remained unchanged at 42,66,22,217 shares of Rs 10 each.
- Promoter Sachidanand Hariram Upadhyay sold 89,98,598 equity shares, or 2.11% of total share capital
- Holding decreased from 75.11% (32,04,39,246 shares) to 73.00% (31,14,40,648 shares)
- Transaction was executed through the open market on September 29, 2026
- Total paid-up equity capital remains at Rs 426,62,22,170 consisting of 42,66,22,217 equity shares of Rs 10 each
Lords Mark Industries announced it has successfully achieved the mandatory 25% Minimum Public Shareholding (MPS) compliance under SEBI Listing Regulations and SCRR rules. This compliance follows the sale of 1,03,56,983 equity shares on September 18, 2026, and an additional 89,98,598 equity shares on September 29, 2026. Prior to this, promoter holding stood at 79.84% as of June 2026, exceeding regulatory limits. The move resolves potential regulatory non-compliance risks and penalties associated with MPS norms.
- Achieved mandatory 25% Minimum Public Shareholding (MPS) requirement
- Sold 1,03,56,983 equity shares on September 18, 2026
- Sold 89,98,598 equity shares on September 29, 2026
- Complied with Rule 19(2)(b) and Rule 19A of SCRR, 1957, and Regulation 38 of SEBI LODR
Lord's Mark Industries announced that its healthcare platform has registered its AI-powered haemodialysis system (developed by Renalyx Health Systems Pvt. Ltd.) with the UK MHRA under GMDN Code 58131. The company plans to start exporting machines to the UK and allied markets from early January 2027, alongside exploring its own dialysis center operations. The MHRA registration serves as device listing but explicitly does not constitute clinical certification or approval by the UK Competent Authority. Against TTM revenue of ₹993 Cr, the commercial financial scale of this development is currently unquantified.
- Registered with the UK MHRA for haemodialysis system under GMDN Code 58131
- Registration covers manufacturer Renalyx Health Systems Pvt. Ltd. for institutional and home use
- Exports to the UK and allied markets scheduled to begin in early January 2027
- MHRA expressly clarifies that this registration does not constitute UK Competent Authority approval or certification
Promoter and Managing Director Sachidanand Hariram Upadhyay sold 1,03,56,983 equity shares of Lords Mark Industries on September 18, 2026, generating net proceeds of Rs 87.39 crore. The promoter has formally proposed to reinvest the majority of these proceeds back into the company for the expansion of its medical device unit. The total realization represents approximately 8.8% of the company's TTM revenue of Rs 993 crore and about 8.8% of its net worth (Rs 991 crore). The exact mechanism of reinvestment (equity, debt, or warrants) remains subject to determination.
- Promoter sold 1,03,56,983 equity shares via block deal/open market on September 18, 2026
- Net aggregate proceeds received by promoter stand at Rs 87,38,75,210
- Promoter proposes to reinvest the majority of the Rs 87.39 crore proceeds into medical device unit expansion
- Net proceeds represent ~8.8% of TTM revenue of Rs 993 crore
Lord's Mark Industries announced that its Technical Committee has approved the final clinical trial stage for its AI-powered wearable breast cancer screening technology, developed in collaboration with C-MET. Phase 2 trials targeting 98% accuracy are scheduled to commence in January 2027 across India, the USA, Europe, and Great Britain. The company is seeking CDSCO, US FDA, and European approvals, targeting key regulatory clearances before March 2027 and a commercial product launch by April 2027. While addressing an estimated USD 11.4 billion diagnostic market by 2033, commercial revenue realization is at least 6-7 months away and subject to multi-jurisdiction approvals.
- Technical Committee approved final clinical trial stage across USA, Great Britain, and Europe
- Phase 2 trials targeting 98% accuracy to commence from January 2027
- Targeting completion of final trials and key regulatory milestones before March 2027
- Targeting commercial placement and launch of the device by April 2027
- Global breast cancer diagnostics market projected to reach USD 11.4 billion by 2033
Lords Mark Industries Limited has published its 46th Annual Report for FY 2025-26 under Regulation 34(1) of SEBI LODR Regulations. The 46th Annual General Meeting is scheduled for Wednesday, September 30, 2026, via Video Conferencing. Key agenda items include adoption of FY26 financial statements and appointment of M/s Sanjeev S Gupta & Associates as statutory auditors for a 5-year term until 2031. The report also highlights its business verticals across Healthcare Diagnostics, Biotech, and Renewable Energy.
- 46th Annual General Meeting convened for September 30, 2026 at 11:30 AM via VC/OAVM
- Proposed appointment of Statutory Auditors M/s Sanjeev S Gupta & Associates for a 5-year term ending at the 51st AGM in 2031
- Proposed appointment of Secretarial Auditor CS Geeta Serwani for 5 consecutive fiscal years (FY27 to FY31)
- Distribution network covers 200+ partners nationwide across public and private healthcare sectors
Lords Mark Industries released its Q1 FY27 investor call transcript following its recent reverse-merger listing. The company reported Q1 topline of approximately ₹280 crore and bottomline of ₹32 crore, with 55% revenue contributed by IVD & Medtech and 45% by Renewable Energy. Management disclosed an active renewable energy order book of around ₹3,000 crore and guided for over ₹2,000 crore in annual revenue with 10-11% PAT margins by FY28. To comply with the 75% minimum public shareholding rule, the company is evaluating an OFS, rights issue, or QIP to dilute its current ~80% promoter holding.
- Renewable energy order book stands at approximately ₹3,000 crore
- Targets crossing ₹2,000+ crore revenue with 10-11% PAT margin by FY28
- Q1 FY27 revenue mix was 55% IVD & Medtech (20% EBITDA margin) and 45% Renewable Energy (11% EBITDA margin)
- Planning equity dilution via OFS/rights/QIP to reduce promoter holding from ~80% to 75%
- Dialysis machine commercial production started with Bharat Electronics (BEL) as manufacturing partner
Lords Mark Industries Limited has uploaded the audio and video recording of its investor conference call held on August 19, 2026. The call, organized by Financial Mindss (JaiBharti Capital Advisory), discussed the company's business progress, operational updates, and Q1 FY27 performance. This is a routine compliance filing under Regulations 30 and 46 of the SEBI LODR Regulations, 2015.
- Investor call conducted and concluded at 06:00 p.m. IST on August 19, 2026
- Call covered business progress, operational developments, and Q1 FY27 performance updates
- Conference call was organized by Financial Mindss (JaiBharti Capital Advisory Private Limited)
- Filing submitted pursuant to Regulations 30 and 46 of SEBI LODR Regulations
Infomerics Valuation and Rating Ltd has upgraded the credit ratings for Lord's Mark Industries Limited's bank loan facilities. The long-term rating has been upgraded to IVR A-/Stable, and the short-term rating has been revised upward to IVR A2+. Additionally, the total quantum of rated bank facilities has been enhanced from ₹191.03 crore to ₹260.37 crore. The rating is valid for one year through August 16, 2027.
- Long-term bank facility rating upgraded to IVR A-/Stable by Infomerics
- Short-term bank facility rating upgraded to IVR A2+
- Total rated bank facilities enhanced to ₹260.37 crore from ₹191.03 crore
- Rating review took into account performance for FY25 (Audited) and FY26 (Provisional)
Lords Mark Industries has been invited to participate in an investor meet organized by Financial Mindss (JaiBharti Capital Advisory Private Limited). The virtual interaction is scheduled for Wednesday, August 19, 2026, at 4:00 PM IST. The management is expected to discuss the company's ongoing business progress, operations, and performance following its Jun 2026 quarter revenue of ₹307.68 cr.
- Meeting scheduled for Wednesday, 19th August 2026 at 04:00 p.m. IST
- Organized by Financial Mindss (JaiBharti Capital Advisory Private Limited)
- Interaction to be conducted via online mode to discuss business progress
- Follows Jun 2026 quarterly revenue of ₹307.68 cr and net profit of ₹33.18 cr
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
